Qiagen, Biotype Diagnostics joint venture, 10/15

Qiagen and Biotype Diagnostics have entered into a partnership to establish Biotype Innovation GmbH. The new company will develop and commercialize molecular diagnostic workflows initially for personalized health care applications based on Qiagen’s proprietary ModaPlex platform, which enables customers to detect, characterize, and measure up to 100 parameters simultaneously.

The diagnostic assays developed by Biotype Innovation are expected to add to the assay menu of the ModaPlex platform, especially in the market for companion diagnostics. Qiagen will contribute technology and access to its global commercialization engine to the joint venture, while Biotype Diagnostics will contribute know-how, assay development resources, and its scientific network. Qiagen will have worldwide distribution rights for the assays and Biotype Diagnostics will have co-distribution rights for Germany, Austria, and Switzerland.

The head office will be based in Hellerau in Dresden, Germany, on the Biotype Diagnostics campus and is expected to be fully operational by the third quarter of 2015.

Qiagen, 240-686-7425